BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities

April 7, 2017

Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture capitalist’s EUR 160 million fund will prosper from the increased understanding of human and microbe interactions. Seventure has just published a report on the emergence of the microbiome as an intense area of interest in the biotech industry, starting with the advent of deep sequencing technology in the early 2000s and moving toward the Phase II trials in progress now.

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Video
BIO-Europe Spring® 2017:  Infant Bacterial Therapeutics harnesses microbiome to treat preterm babies
BIO-Europe Spring® 2017: Infant Bacterial Therapeutics harnesses microbiome to treat preterm babies

By harvesting Lactobacillus reuteri from lactating mothers, Infant Bacterial Therapeutics has developed an ...

Next Video
BIO-Europe Spring® 2017: Digimed and diagnostics: Market access and new collaborations
BIO-Europe Spring® 2017: Digimed and diagnostics: Market access and new collaborations

The effect of digital medicine on diagnostics is having and will continue to have a revolutionary effect on...